ARWR Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of 33.55%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Amgen, Inc.'s return on equity of 95.55%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $57.67, signalling downside risk potential of -15.94%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could grow by 0.94%. Given that Amgen, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Amgen, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, which suggesting that the stock is 27.862% more volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.96% to investors and pays a quarterly dividend of $2.38 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 24.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 11.04x versus 4.85x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of -82.06%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $57.67, signalling downside risk potential of -15.94%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.86%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, which suggesting that the stock is 27.862% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 11.04x versus 13.88x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of 28.26%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Novartis AG's return on equity of 33.87%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $57.67, signalling downside risk potential of -15.94%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could grow by 3.62%. Given that Novartis AG has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Novartis AG is more attractive than Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, which suggesting that the stock is 27.862% more volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.07% to investors and pays a quarterly dividend of $3.99 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are smaller than Novartis AG quarterly revenues of $13.9B. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is lower than Novartis AG's net income of $3.9B. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Novartis AG's PE ratio is 17.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 11.04x versus 4.71x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of -45.06%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $57.67, signalling downside risk potential of -15.94%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $19.91 which suggests that it could fall by -8.93%. Given that Arrowhead Pharmaceuticals, Inc. has more downside risk than Sarepta Therapeutics, Inc., analysts believe Sarepta Therapeutics, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, which suggesting that the stock is 27.862% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.348%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 11.04x versus 0.93x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.